Ohio pharmacy board bars compounded semaglutide and tirzepatide copies

Ohio's board of pharmacy has issued GLP-1 compounding guidance that treats semaglutide and tirzepatide as no longer compoundable copies of approved drugs now that shortages have ended. The July 2025 guidance also expressly prohibits the investigational peptides retatrutide and cagrilintide and requires that active pharmaceutical ingredients be purchased from an Ohio-licensed distributor ^[1].

The guidance largely restates federal law. Semaglutide and tirzepatide were never placed on the FDA's 503A or 503B bulk substances lists; their compounding was permitted only through a drug shortage pathway, and that pathway closed as the FDA resolved the tirzepatide and semaglutide shortages ^[1]. The FDA has since reinforced its position through compliance policy guidance on what makes a compounded product "essentially a copy" of an approved drug, a proposal to exclude these molecules from the 503B bulks list, and successive waves of warning letters to compounders and telehealth marketers of compounded GLP-1 products ^[1].

What sets Ohio apart is enforcement rather than the substance of the rule. The state board reports summarily suspending more than thirty clinics and medical spas since the beginning of 2025 ^[1]. Washington is the other state identified as an active enforcer: its Pharmacy Quality Assurance Commission issued a semaglutide statement and then imposed a stop-service order on a GLP-1 sterile compounder for sterile compounding and licensure failures ^[1].

The legal form of a state's position matters. Only California has enacted a GLP-1-relevant rule with the force of law — revised compounding regulations effective October 1, 2025, that require pharmacists to verify and document a clinically significant, patient-specific difference and require that a certificate of analysis name the active ingredient manufacturer, not merely the distributor ^[1]. Board guidance, newsletters, position statements and attorney general alerts in other states inform enforcement but do not carry the same legal force as a promulgated regulation ^[1].

Other states follow different models. Alabama and New Jersey issued position statements or declaratory rulings on semaglutide compounding, typically prohibiting salt forms and requiring pharmaceutical-grade active ingredients from an FDA-registered source with a valid certificate of analysis, without adding an enforceable state rule beyond the federal standard ^[1]. Connecticut's pharmacy regulator has taken no GLP-1 position, but the state attorney general has run an enforcement campaign under the state's unfair trade practices statute against distributors, med spas and clinics ^[1]. Texas and Florida are representative of a larger group of states with no official GLP-1 or peptide-specific board position, regulating compounding through general frameworks that already incorporate the "essentially a copy" limitation ^[1].

Why it matters for patients

Compounded semaglutide and tirzepatide sold in Ohio now fall outside the pathway the FDA allowed during the shortage, which means the products themselves — not just the sellers — are the focus of the state's position ^[1]. Patients in Ohio who have been buying compounded versions may find them harder to obtain.

Ohio's guidance names retatrutide and cagrilintide directly. Neither is FDA-approved, and both are expressly prohibited in certain jurisdictions, including Ohio ^[1].

Enforcement reaches the businesses that dispense these products. More than thirty Ohio clinics and medical spas have been summarily suspended since the start of 2025, according to the board, so a patient's regular source of a compounded product could close or stop selling it ^[1].

It is not yet known how Ohio's board will apply the guidance to prescriptions already written or filled, or whether every Ohio pharmacy will stop selling compounded semaglutide and tirzepatide. That has not been reported.

What happens next

California's revised compounding regulations take effect October 1, 2025 ^[1]. Because most states default to the federal standard, federal decisions on GLP-1s and peptides largely drive what states do next; California is expected to remain a distinct compliance jurisdiction, and enforcement-heavy states like Ohio and Washington are expected to stay higher risk regardless of where the substantive rule lands ^[1]. Any further Ohio actions, such as additional disciplinary cases, have not been disclosed.